Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $8.56, but opened at $9.15. Ginkgo Bioworks shares last traded at $9.82, with a volume of 318,456 shares changing hands.
Analyst Ratings Changes
Separately, TD Cowen lifted their price objective on Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a "buy" rating in a report on Friday, September 20th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, Ginkgo Bioworks presently has an average rating of "Hold" and an average target price of $4.58.
View Our Latest Analysis on DNA
Ginkgo Bioworks Stock Performance
The firm has a fifty day simple moving average of $9.20. The firm has a market capitalization of $535.70 million, a price-to-earnings ratio of -0.71 and a beta of 1.09.
Institutional Trading of Ginkgo Bioworks
A number of hedge funds have recently bought and sold shares of DNA. Wellington Wealth Strategies LLC. acquired a new stake in shares of Ginkgo Bioworks in the second quarter valued at approximately $41,000. PDT Partners LLC purchased a new stake in Ginkgo Bioworks in the 3rd quarter valued at $1,199,000. Erste Asset Management GmbH acquired a new stake in shares of Ginkgo Bioworks in the 3rd quarter worth $4,075,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Ginkgo Bioworks during the 3rd quarter worth $2,282,000. Finally, Benjamin F. Edwards & Company Inc. boosted its position in shares of Ginkgo Bioworks by 1,606.9% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 234,836 shares of the company's stock valued at $79,000 after acquiring an additional 221,078 shares during the last quarter. Institutional investors and hedge funds own 78.63% of the company's stock.
About Ginkgo Bioworks
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Recommended Stories
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
